Catheter Precision (NYSEAMERICAN:VTAK) Trading Up 6.8% – Should You Buy?

Catheter Precision, Inc. (NYSEAMERICAN:VTAK)’s stock price rose 6.8% during mid-day trading on Friday . The company traded as high as $0.21 and last traded at $0.21. Approximately 879,451 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 5,109,958 shares. The stock had previously closed at $0.1966.

Catheter Precision Stock Up 6.8%

The firm has a market capitalization of $3.02 million, a price-to-earnings ratio of -0.03 and a beta of -1.03. The company has a current ratio of 0.19, a quick ratio of 0.18 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $0.87.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.The firm had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $2.00 million.

Institutional Trading of Catheter Precision

An institutional investor recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is currently owned by institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.